Anti-glyco-MUC1 antibodies and their uses
AssigneeGO Therapeutics, Inc.
InventorThayer White
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to anti-glyco-MUC1 antibodies and antigen binding fragments thereof that specifically bind to a cancer-specific glycosylation variant of MUC1 and related fusion proteins and antibody-drug conjugates, as well as nucleic acids encoding such biomolecules. The present disclosure further relates to use of the antibodies, antigen-binding fragments, fusion proteins, antibody-drug conjugates and nucleic acids for cancer therapy.
Claims32
A method of treating cancer comprising administering to a subject in need thereof an effective amount of an anti-glyco-MUC1 antibody or antigen binding fragment that:
- a. comprises a complementarity determining region (CDR) H1 comprising the amino acid sequence of SEQ ID NO:33, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:29, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:25, a CDR-L1 comprising the amino acid sequence of SEQ ID NO:
- 8, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:9, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:31;
- and
- b. binds to the MUC1 tandem repeat (VTSAPDTRPAPGSTAPPAHG)3 (SEQ ID NO:47) that has been glycosylated in vitro using purified recombinant human glycosyltransferases GalNAc-T1, GalNAc-T2, and GalNAc-T4 (referred to hereinafter as the “first epitope”).
A method of treating cancer comprising administering to a subject in need thereof an effective amount of an anti-glyco-MUC1 antibody or antigen binding fragment that:
- a. comprises a complementarity determining region (CDR) H1 comprising the amino acid sequence of SEQ ID NO:33, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:29, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:25, a CDR-L1 comprising the amino acid sequence of SEQ ID NO:
- 8, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:9, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:31;
- and
- b. preferentially binds to a glyco-MUC1 epitope that is overexpressed on cancer cells as compared to normal cells.
A method detecting cancer in a biological sample, comprising contacting a sample with an anti-glyco-MUC1 antibody or antigen-binding fragment and detecting binding of the anti-glyco-MUC1 antibody or antigen-binding fragment, wherein the anti-glyco-MUC1 antibody or antigen-binding fragment:
- a. comprises a complementarity determining region (CDR) H1 comprising the amino acid sequence of SEQ ID NO:33, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:29, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:25, a CDR-L1 comprising the amino acid sequence of SEQ ID NO:
- 8, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:9, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:31;
- and
- b. binds to the MUC1 tandem repeat (VTSAPDTRPAPGSTAPPAHG)3 (SEQ ID NO:47) that has been glycosylated in vitro using purified recombinant human glycosyltransferases GalNAc-T1, GalNAc-T2, and GalNAc-T4.
A method detecting cancer in a biological sample, comprising contacting a sample with an anti-glyco-MUC1 antibody or antigen-binding fragment and detecting binding of the anti-glyco-MUC1 antibody or antigen-binding fragment, wherein the anti-glyco-MUC1 antibody or antigen-binding fragment:
- a. comprises a complementarity determining region (CDR) H1 comprising the amino acid sequence of SEQ ID NO:33, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:29, a CDR-H3 comprising the amino acid sequence of SEQ ID NO:25, a CDR-L1 comprising the amino acid sequence of SEQ ID NO:
- 8, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:9, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:31;
- and
- b. preferentially binds to a glyco-MUC1 epitope that is overexpressed on cancer cells as compared to normal cells.
Dependencies are inferred from the claim text.